2,4-thiazolidinedione has been researched along with exenatide in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brodows, RG; Durán García, S; Giaconia, JM; Hoogwerf, BJ; Kim, DD; Milton, DR; Trautmann, ME; Zinman, B | 1 |
| Malozowski, S | 1 |
| Brown, A; Desai, M; Taneja, D; Tannock, LR | 1 |
| Dotta, F; Festa, A; Gallwitz, B; Guerci, B; Kiljański, J; Rosas-Guzmán, J; Schernthaner, G; Simó, R; Zhou, M | 1 |
| Ojo, O | 1 |
2 review(s) available for 2,4-thiazolidinedione and exenatide
| Article | Year |
|---|---|
Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management.
Topics: Amyloid; Bariatric Surgery; Diabetes Mellitus; Diet, Reducing; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Exercise; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Islet Amyloid Polypeptide; Liraglutide; Metformin; Obesity; Peptides; Thiazolidinediones; Treatment Failure; Venoms; Weight Loss | 2010 |
The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review.
Topics: Biomarkers; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Exenatide; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Peptides; Risk Factors; Thiazolidinediones; Venoms | 2016 |
2 trial(s) available for 2,4-thiazolidinedione and exenatide
| Article | Year |
|---|---|
The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
Topics: Adult; Aged; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Injections, Subcutaneous; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Nausea; Peptides; Thiazolidinediones; Venoms; Vomiting; Weight Loss | 2007 |
Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Europe; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Peptides; Prospective Studies; Sulfonylurea Compounds; Thiazolidinediones; Treatment Failure; Venoms | 2015 |
2 other study(ies) available for 2,4-thiazolidinedione and exenatide
| Article | Year |
|---|---|
Summaries for patients. Exenatide therapy for type 2 diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Male; Metformin; Middle Aged; Nausea; Peptides; Thiazolidinediones; Venoms; Vomiting; Weight Loss | 2007 |
Exenatide in combination therapy: small study, big market, and many unanswered questions.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Metformin; Peptides; Research Design; Thiazolidinediones; Venoms | 2007 |